{"id":"https://openalex.org/W2010865381","doi":"https://doi.org/10.1016/j.bmcl.2007.09.051","title":"Aminocyclohexylsulfonamides: Discovery of metabolically stable \u03b11a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)","display_name":"Aminocyclohexylsulfonamides: Discovery of metabolically stable \u03b11a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)","publication_year":2007,"publication_date":"2007-09-19","ids":{"openalex":"https://openalex.org/W2010865381","doi":"https://doi.org/10.1016/j.bmcl.2007.09.051","mag":"2010865381","pmid":"https://pubmed.ncbi.nlm.nih.gov/17904840"},"language":"en","primary_location":{"id":"doi:10.1016/j.bmcl.2007.09.051","doi":"https://doi.org/10.1016/j.bmcl.2007.09.051","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.bmcl.2007.09.051","pdf_url":null,"source":{"id":"https://openalex.org/S30970080","display_name":"Bioorganic & Medicinal Chemistry Letters","issn_l":"0960-894X","issn":["0960-894X","1464-3405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & Medicinal Chemistry Letters","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"George Chiu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"George Chiu","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Shengjian Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shengjian Li","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019899524","display_name":"Hong Yan Cai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hong Cai","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082297714","display_name":"Peter J. Connolly","orcid":"https://orcid.org/0009-0001-3425-5015","observed_orcids":["https://orcid.org/0009-0001-3425-5015"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter J. Connolly","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110255243","display_name":"Sean X. Peng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sean Peng","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019977474","display_name":"Kathe L. Stauber","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathe Stauber","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066409214","display_name":"Virginia L. Pulito","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Virginia Pulito","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059502578","display_name":"Jingchun Liu","orcid":"https://orcid.org/0000-0003-3279-4071","observed_orcids":["https://orcid.org/0000-0003-3279-4071"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jingchun Liu","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112474366","display_name":"Steven A. Middleton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven A. Middleton","raw_affiliation_strings":["Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Pharmaceutical Research and Development L.L.C., PO Box 300, 1000 Route 202 South, Raritan, NJ 08869, USA","institution_ids":["https://openalex.org/I4405282460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405282460"],"apc_list":{"value":3880,"currency":"USD","value_usd":3880},"apc_paid":null,"fwci":0.5823,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.69415646,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"17","issue":"22","first_page":"6123","last_page":"6128"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.9585000276565552,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.9585000276565552,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.021400000900030136,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.007499999832361937,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alpha-blockers","display_name":"alpha-blockers","score":0.8840000033378601},{"id":"https://openalex.org/keywords/benign-prostatic-hyperplasia","display_name":"benign prostatic hyperplasia","score":0.8840000033378601},{"id":"https://openalex.org/keywords/lower-urinary-tract-symptoms","display_name":"lower urinary tract symptoms","score":1.0},{"id":"https://openalex.org/keywords/metabolic-stability","display_name":"metabolic stability","score":0.6420000195503235},{"id":"https://openalex.org/keywords/liver-microsomal-metabolism","display_name":"liver microsomal metabolism","score":0.871999979019165},{"id":"https://openalex.org/keywords/tamsulosin","display_name":"tamsulosin","score":0.8029999732971191},{"id":"https://openalex.org/keywords/drug-discovery","display_name":"drug discovery","score":0.5149999856948853}],"concepts":[{"id":"https://openalex.org/C2780542891","wikidata":"https://www.wikidata.org/wiki/Q418480","display_name":"Tamsulosin","level":3,"score":0.8058291077613831},{"id":"https://openalex.org/C2779478474","wikidata":"https://www.wikidata.org/wiki/Q446372","display_name":"Lower urinary tract symptoms","level":4,"score":0.794683575630188},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.6883485317230225},{"id":"https://openalex.org/C2777562237","wikidata":"https://www.wikidata.org/wiki/Q835051","display_name":"Hyperplasia","level":2,"score":0.6669936776161194},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.647726833820343},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5240702629089355},{"id":"https://openalex.org/C2991874392","wikidata":"https://www.wikidata.org/wiki/Q1124842","display_name":"Metabolic stability","level":3,"score":0.5211372375488281},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.4951445162296295},{"id":"https://openalex.org/C2778196918","wikidata":"https://www.wikidata.org/wiki/Q4684744","display_name":"Adrenergic antagonist","level":4,"score":0.4775220453739166},{"id":"https://openalex.org/C3454156","wikidata":"https://www.wikidata.org/wiki/Q1144241","display_name":"Side effect (computer science)","level":2,"score":0.4650273323059082},{"id":"https://openalex.org/C77411442","wikidata":"https://www.wikidata.org/wiki/Q181100","display_name":"Urinary system","level":2,"score":0.46009060740470886},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.4405463635921478},{"id":"https://openalex.org/C64943373","wikidata":"https://www.wikidata.org/wiki/Q2651003","display_name":"Alpha (finance)","level":4,"score":0.4155252277851105},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39701685309410095},{"id":"https://openalex.org/C2776235491","wikidata":"https://www.wikidata.org/wiki/Q9625","display_name":"Prostate","level":3,"score":0.27670007944107056},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.1785644292831421},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.144828200340271},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.1352623999118805},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.10233744978904724},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C49453240","wikidata":"https://www.wikidata.org/wiki/Q1592163","display_name":"Construct validity","level":3,"score":0.0},{"id":"https://openalex.org/C2775944032","wikidata":"https://www.wikidata.org/wiki/Q22907659","display_name":"Patient satisfaction","level":2,"score":0.0},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000317","descriptor_name":"Adrenergic alpha-Antagonists","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D000317","descriptor_name":"Adrenergic alpha-Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000317","descriptor_name":"Adrenergic alpha-Antagonists","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D001667","descriptor_name":"Binding, Competitive","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003514","descriptor_name":"Cyclohexylamines","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D003514","descriptor_name":"Cyclohexylamines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D003514","descriptor_name":"Cyclohexylamines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004355","descriptor_name":"Drug Stability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008861","descriptor_name":"Microsomes","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008861","descriptor_name":"Microsomes","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D011470","descriptor_name":"Prostatic Hyperplasia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.bmcl.2007.09.051","doi":"https://doi.org/10.1016/j.bmcl.2007.09.051","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.bmcl.2007.09.051","pdf_url":null,"source":{"id":"https://openalex.org/S30970080","display_name":"Bioorganic & Medicinal Chemistry Letters","issn_l":"0960-894X","issn":["0960-894X","1464-3405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & Medicinal Chemistry Letters","raw_type":"journal-article"},{"id":"pmid:17904840","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17904840","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & medicinal chemistry letters","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W1526092273","https://openalex.org/W1870803056","https://openalex.org/W1972734008","https://openalex.org/W1978889707","https://openalex.org/W1993879387","https://openalex.org/W2008168996","https://openalex.org/W2009516949","https://openalex.org/W2021419143","https://openalex.org/W2049127257","https://openalex.org/W2057529493","https://openalex.org/W2059522062","https://openalex.org/W2060300060","https://openalex.org/W2073123650","https://openalex.org/W2075491849","https://openalex.org/W2086157441","https://openalex.org/W2096556143","https://openalex.org/W2098261166","https://openalex.org/W2119008659","https://openalex.org/W2125685489","https://openalex.org/W3144493291","https://openalex.org/W4239436415","https://openalex.org/W4252695254"],"related_works":["https://openalex.org/W2057529493","https://openalex.org/W4252695254","https://openalex.org/W4251561203","https://openalex.org/W2005717683","https://openalex.org/W2889003985","https://openalex.org/W2068623148","https://openalex.org/W4417302564","https://openalex.org/W4391649180","https://openalex.org/W4249700090","https://openalex.org/W2060754347"],"abstract_inverted_index":null,"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2016-06-24T00:00:00"}